In the literature, some data suggesting a protective role of SGLT2-i from CI-AKI are available, but only in specific settings such as diabetes, chronic kidney disease (CKD) patients and patients with AMI undergoing primary PCI. This evidence concerns the gene SLC5A2 and diabetes mellitus.